One of the biggest decisions in a cardiologist's life is knowing when, exactly, to start a family. Nandita S. Scott, MD, co-director of the Corrigan Women's Heart Health Program at Mass General Hospital, shared her perspective on this important topic.
"I think we really need our cardiologist community to understand the changes that are happening with value-based payment," one expert tells Cardiovascular Business.
Interventional cardiologist Foluso Fakorede, MD, says everything from limited specialists to a lack of sidewalks are causing a disproportionate rate of minorities to be caught in the current PAD and CLI epidemic.
Jeffrey Kuvin, MD, one of the leading voices behind efforts to create a new Board of Cardiovascular Medicine, spoke with Cardiovascular Business about where things stand today.
"Changing just six alerts in the system knocked out about 5 million alerts annually," explained Patrick McGill, MD, executive vice president and chief transformation officer at CHN.
The mitral valve has been an especially challenging target for transcatheter interventions, but there are reasons to think key breakthroughs are on the horizon. We talked to Kendra Grubb, MD, about this and other ongoing trends at TCT 2023.
Kendra Grubb, MD, one of the country's leading experts on cardiac surgery, discussed what she tells her patients when they ask if TAVR is better than SAVR for treating severe aortic stenosis.
Could this late-breaking clinical trial from TCT 2023 be a sign of things to come in the years ahead? Samir Kapadia, MD, explored the topic in a new interview.
Robert Yeh, MD, detailed the importance of the pivotal AGENT IDE trial, which focused on the use of a paclitaxel-coated balloon to treat in-stent restenosis.
